Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "REACH"

1151 News Found

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
interviews | December 10, 2025

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines


Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids
Biopharma | December 10, 2025

Croda strikes strategic deal with Amino to boost global supply of high-purity amino acids

The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities


Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
News | December 10, 2025

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors


Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
News | December 09, 2025

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones


Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug
News | December 09, 2025

Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma


Paradigm Health to acquire Flatiron’s clinical research business
News | December 07, 2025

Paradigm Health to acquire Flatiron’s clinical research business

It's an acquisition that aims at forming one of the US's largest oncology trial networks


Merck Animal Health wins FDA’s fast-track green light for first-in-decades cattle parasite treatment
Drug Approval | December 06, 2025

Merck Animal Health wins FDA’s fast-track green light for first-in-decades cattle parasite treatment

The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation


Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma
Drug Approval | December 06, 2025

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population


Fortis ropes in 'Yamraj' to launch nationwide helmet safety drive
Hospitals | December 05, 2025

Fortis ropes in 'Yamraj' to launch nationwide helmet safety drive

This campaign is to raise awareness about the crucial role helmet usage plays in saving lives